opioids

Showing 15 posts of 86 posts found.

shutterstock_57369385

European Commission approves first and only long-acting opioid dependence therapy

November 26, 2018
Sales and Marketing Europe, opioid crisis, opioids, pharma

Europe has seen its first and only approval of a long-acting therapy for opioid dependence, as the European Commission (EC) …

opioid_crisis

Opioid use disorder market to hit $4.8 billion by 2027, says GlobalData

November 26, 2018
Sales and Marketing US, opioid crisis, opioids, pharma

New findings released by analytics firm GlobalData indicates that the market for opioid use disorder therapies is set to grow …

shutterstock_138095450

Opioid dependency therapy price hiked 600% since 2014, Senate investigators find

November 20, 2018
Manufacturing and Production, Sales and Marketing Evzio, Kaleo, Senate, US, naloxone, opioid crisis, opioid epidemic, opioids, pharma

Senate investigators have found that Virginia-based drugmaker Kaleo hiked the price of its opioid dependency therapy Evzio (naloxone) by as …

5204602349_c87b204860_z

FDA commissioner Scott Gottlieb says that more rigorous approval process would be unique to opioids

November 12, 2018
Sales and Marketing FDA, Gottlieb, opioid crisis, opioids

Food and Drug Administration (FDA) commissioner Scott Gottlieb has said that if a more rigorous approval process is introduced for …

opioid_pills

Alabama’s biggest insurer will no longer cover OxyContin prescriptions

November 9, 2018
Medical Communications Alabama, Blue Cross and Blue Shield, OxyContin, insurance, opioids

The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision …

FDA controversially approves potent opioid up to ten times stronger than fentanyl

November 6, 2018
Sales and Marketing Dsuvia, FDA, US, fentanyl, opioid crisis, opioids, pharma

Despite voices of criticism, the FDA has opted to approve AcelRX’s Dsuvia (sufentanil), an opioid medication said to be five …

5204602349_c87b204860_z

FDA advisory panel approves AcelRx’s opioid pain drug Dsuvia

October 15, 2018
Sales and Marketing FDA, approval, comittee, opioids

An FDA advisory panel voted 10 to 3 to recommend the approval of AcelRx Pharmaceuticals’ opioid pain drug Dsuvia (sufentanil) …

5204602349_c87b204860_z

FDA expand REMS education program in effort against opioid crisis

September 19, 2018
Research and Development FDA, IR, opioid crisis, opioids, rems

The US Food and Drug Administration is set to introduce a requirement that all healthcare providers be offered educational training …

shutterstock_168864905

Emergent snaps up Adapt and its opioid overdose therapy for $735m

August 29, 2018
Research and Development, Sales and Marketing Emergent, Narcan, naloxone, opioid crisis, opioids, pharma

Emergent BioSolutions has announced it has signed an agreement to acquire Adapt Pharma at a valuation of $735 million, a …

Pain Therapeutics refocuses on Alzheimer’s after FDA turns down abuse-deterrent opioid painkiller

August 7, 2018
Manufacturing and Production, Research and Development, Sales and Marketing FDA, Remoxy, opioid crisis, opioids, pain therapeutics, pharma

The FDA has voted to reject Texas-based Pain Therapeutics’ abuse deterrent opioid painkiller Remoxy (oxycodone), leading the company to consider …

Fentanyl-related deaths spike in England and Wales

August 7, 2018
Manufacturing and Production fentanyl, heroin, ons, opioid crisis, opioids, statistics

Deaths linked to the powerful opioid fentanyl have increased by 30% in England and Wales. Figures from the Office for …

Allergan sues Pfizer over opioid crisis lawsuits

August 3, 2018
Medical Communications Allergan, Litigation, Pfizer, lawsuits, opioid crisis, opioids

Allergan are suing American pharma giant Pfizer over potential damages that they may be forced to pay relating to hundreds …

fdaoutsideweb

FDA panels vote to reject Pain Therapeutics’ abuse-deterrent opioid drug

June 27, 2018
Research and Development, Sales and Marketing Remoxy, opioid crisis, opioids, pain therapeutics, pharma

Drug development firm Pain Therapeutics has revealed that its abuse-deterrent opioid medication Remoxy has been rejected by an FDA advisory …

920x920

Purdue culls 350 positions, eradicates sales force

June 21, 2018
Medical Communications, Sales and Marketing Purdue Pharma, opioid crisis, opioids, pharma

Bowing to the pressure applied by external groups for the part it has played in the ongoing opioid crisis, Purdue …

Latest content